In the technology and semiconductor sectors, NVIDIA's profit margins are often seen as the industry benchmark, but a new deal in the biotechnology sector has shattered this perception. Recently, Precigenetics, a biotechnology company specializing in live cell drug development, announced the signing of a letter of intent for a $2.3 million collaboration with scientific instrument giant Thermo Fisher Scientific.
